Weaver Consulting Group Reduces Position in Johnson & Johnson Stock (NYSE:JNJ)

0

Weaver Consulting Group lowered its position in Johnson & Johnson (NYSE:JNJ – Get Rating) shares by 3.5% in Q1, according to its latest 13F filing with the Securities & Exchange Commission. The company held 5,748 shares of the company after selling 206 shares during the period. Weaver Consulting Group’s holdings in Johnson & Johnson were worth $1,019,000 at the end of the last reporting period.

Several other institutional investors have also increased or reduced their stake in the stock. Motco increased its stake in Johnson & Johnson by 2.3% in the 1st quarter. Motco now owns 101,691 shares of the company worth $18,023,000 after purchasing an additional 2,258 shares last quarter. Arete Wealth Advisors LLC increased its stake in Johnson & Johnson by 4.0% in the 1st quarter. Arete Wealth Advisors LLC now owns 17,426 shares of the company worth $3,088,000 after purchasing an additional 666 shares last quarter. Papp L Roy & Associates increased its stake in Johnson & Johnson by 1.7% in the 1st quarter. Papp L Roy & Associates now owns 113,894 shares of the company worth $20,185,000 after purchasing an additional 1,858 shares last quarter. NTV Asset Management LLC increased its stake in Johnson & Johnson shares by 0.7% in Q1. NTV Asset Management LLC now owns 35,565 shares of the company worth $6,303,000 after acquiring 237 additional shares in the last quarter. Finally, Camden Capital LLC increased its stake in Johnson & Johnson shares by 8.2% in the 1st quarter. Camden Capital LLC now owns 3,834 shares of the company worth $680,000 after acquiring 290 additional shares in the last quarter. 68.78% of the shares are currently held by institutional investors.

Analyst upgrades and downgrades

JNJ has been the subject of several research reports. Credit Suisse Group raised its price target on Johnson & Johnson shares from $200.00 to $205.00 and gave the stock an “outperform” rating in a Wednesday, April 20 research note. Morgan Stanley raised its price target on Johnson & Johnson shares from $173.00 to $174.00 and gave the stock an “equal weight” rating in a Friday, July 8 research note. SVB Leerink reduced its price target on Johnson & Johnson shares from $200.00 to $194.00 in a Wednesday July 20 research note. UBS Group reduced its price target on Johnson & Johnson shares from $185.00 to $180.00 in a Thursday, July 21 research note. Finally, Citigroup reduced its price target on Johnson & Johnson shares from $205.00 to $201.00 in a Wednesday, July 20 research note. Four research analysts gave the stock a hold rating, five issued a buy rating and one issued a strong buy rating for the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $189.89.

Johnson & Johnson Stock Performance

NYSE JNJ shares opened at $165.30 on Friday. The company’s 50-day moving average price is $174.25 and its 200-day moving average price is $174.66. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt ratio of 0.37. The company has a market capitalization of $434.60 billion, a PE ratio of 24.06, a PEG ratio of 3.18 and a beta of 0.59. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last reported quarterly results on Tuesday, July 19. The company reported earnings per share (EPS) of $2.59 for the quarter, beating analyst consensus estimates of $2.57 by $0.02. The company posted revenue of $24.02 billion for the quarter, versus a consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The company’s quarterly revenue increased 3.0% from the same quarter last year. During the same quarter last year, the company posted EPS of $2.48. As a group, analysts expect Johnson & Johnson to post EPS of 10.05 for the current year.

Johnson & Johnson announces dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6. Investors of record on Tuesday, August 23 will receive a dividend of $1.13. This represents a dividend of $4.52 on an annualized basis and a dividend yield of 2.73%. The ex-date of this dividend is Monday, August 22. Johnson & Johnson’s payout ratio is 65.79%.

Insider buying and selling

In a similar vein, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a trade that took place on Friday, June 10. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company, valued at $12,336,803. The transaction was disclosed in a legal filing with the SEC, accessible via this link. In other Johnson & Johnson news, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a deal that took place Friday, June 10. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares of the company, valued at approximately $12,336,803. The transaction was disclosed in a document filed with the SEC, which is available via this hyperlink. Additionally, CAO Robert J. Decker sold 8,462 shares of the company in a trade that took place on Thursday, May 26. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. As a result of the sale, the accounting chief now owns 15,473 shares of the company, valued at around $2,785,140. The disclosure of this sale can be found here. 0.35% of the shares are currently held by insiders.

Johnson & Johnson Company Profile

(Get an assessment)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

Featured articles

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.

Share.

About Author

Comments are closed.